Investigational protein replacement protects neonatal mice from deadly intestinal disease

Scientists from Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago and colleagues found that an investigational protein replacement – recombinant human insulin-like growth factor 1 and its binding protein-3 (rhIGF-1/BP3) – protected neonatal mice from necrotizing enterocolitis (NEC), a deadly intestinal disease that often strikes extremely premature infants.

Related Keywords

Chicago ,Illinois ,United States ,Ann Roberth Lurie , ,Manne Research Institute ,Pediatric Research ,Stanley Manne Children ,Research Institute ,Lurie Children ,Northwestern University Feinberg School ,Intestinal Disease ,Children ,Enterocolitis ,Growth Factor ,Hospital ,Insulin ,Medicine ,Necrotizing Enterocolitis ,Reclinical ,Protein ,Research ,